GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IN8bio Inc (STU:6JH0) » Definitions » Notes Receivable

IN8bio (STU:6JH0) Notes Receivable : €0.00 Mil (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is IN8bio Notes Receivable?

IN8bio's Notes Receivable for the quarter that ended in Mar. 2025 was €0.00 Mil.


IN8bio Notes Receivable Historical Data

The historical data trend for IN8bio's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IN8bio Notes Receivable Chart

IN8bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial - - - - -

IN8bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

IN8bio Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


IN8bio Notes Receivable Related Terms

Thank you for viewing the detailed overview of IN8bio's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


IN8bio Business Description

Traded in Other Exchanges
Address
350 5th Avenue, Suite 5330, New York, NY, USA, 10118
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

IN8bio Headlines

No Headlines